Codeine is a mild opioid that relieves pain and suppresses coughing by binding to receptors in your brain and spinal cord. On its own, codeine is actually a prodrug, meaning your body must convert it into morphine before it produces most of its painkilling effect. That conversion process, and the genetic differences that affect it, explain why codeine works well for some people and causes serious problems for others.
How Codeine Works in the Brain
Codeine’s primary targets are mu-opioid receptors spread throughout your central nervous system. When codeine (or more precisely, the morphine your body converts it into) locks onto these receptors, it triggers a chain of events inside nerve cells: calcium levels drop, the cells become less excitable, and pain signals traveling to the brain get dampened. The result is a reduction in how much pain you perceive, along with a mild sense of relaxation or euphoria.
Codeine also activates opioid receptors in the brainstem’s cough center, which is why it has been widely used in prescription cough medicines. By quieting the nerve signals that trigger the cough reflex, it can reduce persistent, unproductive coughing. Both the painkilling and cough-suppressing effects are primarily driven by mu-opioid receptors, though kappa-opioid receptors play a smaller supporting role.
Your Liver Does the Real Work
Codeine is relatively weak on its own. To produce meaningful pain relief, it must pass through your liver, where an enzyme called CYP2D6 converts it into morphine. Only about 5 to 10 percent of a codeine dose gets converted this way. The remaining 80 percent or so is broken down into inactive compounds and excreted without producing opioid effects. This limited conversion is part of why codeine is considered a milder opioid compared to drugs like oxycodone or hydrocodone.
The catch is that CYP2D6 activity varies enormously from person to person based on genetics. About 7 to 10 percent of white populations are “poor metabolizers” who convert very little codeine to morphine, meaning the drug barely works for them. On the other end, 1 to 7 percent of white populations (and more than 25 percent of people of Ethiopian descent) are “ultra-rapid metabolizers” who convert far more codeine into morphine than expected. In ultra-rapid metabolizers, morphine levels can reach 20 to 80 times higher than normal. This creates a real risk of overdose from a standard prescription dose. A case published in the New England Journal of Medicine documented serious codeine toxicity in a patient whose genetic profile caused dangerously high morphine conversion, compounded by other medications and reduced kidney function.
Common Side Effects
Codeine produces the same general side effects as other opioids, just typically at lower intensity. Among people taking mild opioids for chronic pain, about 80 percent experience at least one side effect. The most frequent are:
- Constipation (roughly 41 percent of users), caused by opioid receptors in the gut slowing down muscle contractions
- Nausea (about 32 percent), triggered by opioid activity in the brain’s vomiting center
- Drowsiness (around 29 percent), a direct sedating effect on the central nervous system
Constipation is particularly notable because, unlike drowsiness and nausea, your body does not develop much tolerance to it over time. People who take codeine regularly often deal with constipation for as long as they use the drug. Nausea, on the other hand, tends to improve after the first few days.
Respiratory Depression: The Dangerous Effect
The most serious acute risk of any opioid, including codeine, is respiratory depression. The same mu-opioid receptors that block pain signals also exist in brainstem regions that control breathing rhythm. When these receptors are overstimulated, the neurons responsible for triggering each breath become quieter. Breathing slows, becomes shallow, and in severe cases can stop entirely.
At normal prescribed doses in people with typical metabolism, codeine’s effect on breathing is mild. The danger escalates with higher doses, when codeine is combined with alcohol or sedatives, or in ultra-rapid metabolizers whose bodies produce unexpectedly high levels of morphine. Respiratory depression is the primary cause of death in opioid overdose.
Tolerance, Dependence, and Withdrawal
With regular use, your brain adapts to the constant presence of opioids through a process called neuroadaptation. This happens at multiple levels simultaneously. The opioid receptors themselves become less responsive (a process called desensitization). The nerve cells ramp up their internal signaling pathways to counteract the drug’s dampening effect. And broader neural networks adjust their activity to compensate for the ongoing suppression.
Significant tolerance typically develops over days to weeks of consistent use, though subtle forms of tolerance can begin within hours. As tolerance builds, you need more codeine to achieve the same level of pain relief. Physical dependence follows closely behind tolerance. Your nervous system has now recalibrated to function with opioids present, so removing the drug throws those compensatory systems into overdrive.
Codeine withdrawal generally begins 8 to 24 hours after the last dose and lasts 4 to 10 days. Early symptoms include anxiety, muscle aches, sweating, and a runny nose. These intensify over the first two to three days into insomnia, nausea, vomiting, diarrhea, and abdominal cramping. While codeine withdrawal is deeply uncomfortable, it is rarely life-threatening in otherwise healthy adults.
Special Risks for Children
The FDA has placed its strongest warning, a Contraindication, on codeine products for children. Codeine should not be used to treat pain or cough in children younger than 12. It is also contraindicated for pain management after tonsil or adenoid removal in children of any age. These restrictions exist because children, especially those who happen to be ultra-rapid metabolizers, face a disproportionate risk of life-threatening respiratory depression. Several pediatric deaths linked to codeine prompted these regulatory changes, with the FDA first adding a boxed warning in 2013 and later strengthening restrictions. The FDA also recommends against codeine use in breastfeeding women, since morphine produced by the mother’s metabolism can pass to the infant through breast milk.